Temozolomide for recurrent intracranial supratentorial platinum‐refractory ependymoma

• DOI: 10.1002/cncr.24524
• Publication Date: 2009-06-30T20:32:45Z
• Authors: Marc C. Chamberlain; Sandra K. Johnston
• Keywords: Ependymoma; Temozolomide; Carboplatin; Leukopenia; Refractory (planetary science)

To the authors' knowledge, there currently is no standard therapy for platinum-resistant ependymoma; hence, a need exists new therapies. In current study, retrospective evaluation of temozolomide (TMZ) in adults with recurrent, supratentorial, platinum-refractory, World Health Organization grade 2 ependymoma was performed, an objective determining 6-month progression-free survival (PFS).A total 25 patients, ages 28 to 63 years, recurrent were treated. All patients had previously been treated surgery, radiotherapy, and platinum-based chemotherapy (cisplatin 15 carboplatin 10 patients). Nine underwent repeat surgery. Patients at time second recurrence TMZ (5 consecutive days), once every 4 weeks, which defined as single cycle. Neurologic performed weeks neuroradiographic assessment 8 weeks.A 68 cycles (median, cycles; range, 1-6 cycles) administered. TMZ-related toxicity included leukopenia (7 patients; 1 3 [grade determine according National Cancer Institute Common Toxicity Criteria [version 3.0]), constipation (6 none 3), fatigue anemia (2; thrombocytopenia deep vein thrombosis 3). One patient (4%) demonstrated partial radiographic response, 9 (36%) stable disease, (60%) developed progressive disease after TMZ. Time tumor progression ranged from 7 months months). Survival The 12-month PFS 2% 0%, respectively.TMZ this dose schedule little efficacy cohort intracranial, platinum-refractory ependymoma.